Breaking down trending topics, clinical studies, and articles related to alternative mental health therapies including plant based medicine, psychedelic therapy, and functional medicine with the insights of our highly trained clinical pharmacists. Building a community and inspiring hope for those looking to live better! <br/><br/><a href="https://neuralpharm.substack.com?utm_medium=podcast">neuralpharm.substack.com</a>
Neural Pharm Podcast
Claim This Podcastby Colby Burns, PharmD and Christopher Toney, PharmD
5.0(1 reviews)
24 episodes
Updated Bi-weekly
Accepts GuestsHas SponsorsLocation 🇺🇸
40
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality70
Social0
YouTube0
Engagement27
Podcast Overview
Breaking down trending topics, clinical studies, and articles related to alternative mental health therapies including plant based medicine, psychedelic therapy, and functional medicine with the insights of our highly trained clinical pharmacists. Building a community and inspiring hope for those looking to live better! <br/><br/><a href="https://neuralpharm.substack.com?utm_medium=podcast">neuralpharm.substack.com</a>
Language
🇺🇲
Publishing Since
6/7/2023
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
40
Podcast Authority
BetaFairBased on show quality, social media presence, reviews, charts, and more
Quality70
Social0
YouTube0
Engagement27
7
Excellent Areas
3
Good Performance
9
Growth Opportunities
excellent
Episode Length
8 minutes
Performing excellently!
good
Show Experience
24 episodes over 1.6 years
Recommendations available
Unlock the full report to see detailed tips
needs improvement
Publishing Consistency
Every 24 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
1 verified contact email on file for Neural Pharm Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
January 6, 2025
Make America Healthy Again: the Podcast Edition
<p><strong>References: </strong></p><p>Psychedelics legislation in Colorado Springs: https://gazette.com/health/fountain-joins-colorado-springs-in-seeking-to-regulate-fledgling-psychedelic-mushroom-industry/article_22a66456-a1da-11ef-a515-57588c741084.html</p><p>Oregon Psilocybin Ballot Measure Results: https://www.opb.org/article/2024/11/07/psilocybin-ban-mushroom-hallucinogenic-ballot-politics-elections-oregon/</p><p>Vermont Psychedelic Working Group Final Report: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://legislature.vermont.gov/assets/Legislative-Reports/The-Psychedelic-Therapy-Advisory-Working-Group_Final-Report.pdf</p><p>US Life Expectancy Expected to Decline to 66th Globally by 2050: https://www.healthdata.org/news-events/newsroom/news-releases/increases-us-life-expectancy-forecasted-stall-2050-poorer-health#:~:text=Life%20expectancy%20in%20the%20US,2022%20to%2066th%20in%202050</p><p>United Healthcare uses faulty AI to deny claims: https://www.cbsnews.com/news/unitedhealth-lawsuit-ai-deny-claims-medicare-advantage-health-insurance-denials/</p><p>DEA Funding chart: https://crsreports.congress.gov/product/pdf/R/R44576</p><p>See here also, Why is the FDA funded by the companies it regulates?: https://today.uconn.edu/2021/05/why-is-the-fda-funded-in-part-by-the-companies-it-regulates-2/</p><p>Other references to topics discussed on this edition of podcast:</p><p>See Colby’s previous article on Measure 110 in Oregon—which decriminalized nearly all categories of drugs, and has since been overturned: </p><p></p><p>Right to Try bill articles (since this was discussed on this edition of podcast): </p><p>Trump gave patients “Right to Try” but it hasn’t helped them: https://www.statnews.com/2024/08/02/trump-gave-patients-right-to-try-it-hasnt-helped-them/</p><p>DEA says Right to Try doesn’t include substances listed as Schedule I: https://www.marijuanamoment.net/in-case-on-psilocybin-access-for-cancer-patients-dea-says-federal-right-to-try-law-does-not-provide-any-exemptions-from-controlled-substance-act/</p><p>Understanding the Right to Try act: https://pmc.ncbi.nlm.nih.gov/articles/PMC7416898/</p><p></p><p></p><p></p> <br/><br/>Get full access to Neural Pharm at <a href="https://neuralpharm.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4">neuralpharm.substack.com/subscribe</a>
November 20, 2024
Kanna Alkaloids: Nature's MDMA?
Industry expert Dr. Bennett and his team discuss the potential of kanna alkaloids as a natural alternative to MDMA, offering a promising avenue for delayed chronic disease progression and improved mental health outcomes.
August 9, 2024
Breaking down the FDA Advisory Panel Decision on MDMA
<p>**Note this was recorded the first week of July before President Biden announced he would not run for re-election. I know that feels like a lifetime ago but just jump in your time machine for a bit at the beginning of the podcast please. We will likely start our next episode on the pharmacology of Kanna with a “catch up” on Kamala Harris v Trump**</p><p>Footnotes, References and corrections:</p><p>See below to watch the live stream of the FDA advisory panel decision on MDMA Assisted Therapy; a review of the MAPP1 and MAPP2 trial data: </p><p>To review the MAPP1 and MAPP2 trials, listen to our first episode <a target="_blank" href="https://substack.com/@neuralpharm/p-126522144">here</a></p><p>To read about how the FDA is funded, and what “user fees” are <a target="_blank" href="https://www.fda.gov/industry/fda-user-fee-programs/fda-user-fees-explained#:~:text=To%20support%20its%20public%20health,paid%20by%20certain%20other%20entities.">here</a></p><p>To read the open letter from the Heroic Hearts Project (referenced by Chris) on the FDA advisory panel’s decision on veterans mental health, click on this <a target="_blank" href="https://heroicheartsproject.org/exposing-icers-anti-veteran-campaign-against-mdma-assisted-therapy/">link</a>: </p><p>To read a bipartisan letter to President Biden in support of MDMA assisted therapy, click <a target="_blank" href="https://www.ajmc.com/view/bipartisan-letter-to-president-biden-highlights-promise-of-mdma-therapy-for-ptsd">here</a></p><p>To listen to an interview in Psychedelics Today referenced by <strong>Colby</strong> in the podcast with Dr. Amanda Holley, a regulatory consultant and pharmacologist in non-clinical drug development, click <a target="_blank" href="https://podcasts.apple.com/us/podcast/pt522-an-inside-look-at-the-fda-and-early/id1114398275?i=1000659426670"><strong>here</strong></a>. </p><p>To read about GLP1 compounding regulations, and how big pharma is lying about owning exclusivity to semaglutide and tirzepatide, click <a target="_blank" href="http://chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://a4pc.org/files/APC-Compounded-GLP-1s-Media-Brief-REVISED-11-March-2024.pdf">here</a> for a statement from the Alliance for Pharmacy Compounding.</p><p><strong>FACT CHECKS</strong></p><p>—Colby erroneously said the FDA advisory panel reviewed only phase 2 trial data from Lykos; in reality it was phase 3 data from the MAPP1 and MAPP2 trials</p><p>—<a target="_blank" href="https://icer.org/who-we-are/independent-funding/sources-of-funding/">ICER</a>, which is referenced several times in the episode stands for the Institute for Clinical and Economic Review, an organization that discusses the pharmacoeconomic utility of pharmaceutical therapies. <strong>Chris</strong> claimed they were mostly funded by user fees from manufacturers, similar to the FDA, but ICER claims they receive most funding from non-profit sources, with only 14% from manufacturers. To read more about ICER’s letter in regards to MDMA assisted therapy, review my previous article on the topic <a target="_blank" href="https://substack.com/@neuralpharm/p-143252241">here</a>. (Note the Heroic Hearts project uncovered ICER’s potential conflicts of interest not known to me at the time of this publication). </p><p>—Not necessarily a fact check, as at the time we recorded our information was correct, but as news moves quickly it has been revealed through toxicology testing that some Diamond Shruumz products <a target="_blank" href="https://www.statnews.com/2024/07/18/legal-psychedelic-mushrooms-actually-contain-illegal-hallucinogens-study-shows/">do contain psilocybin</a> despite the manufacturers claims they don’t. The FDA possibly didn’t know this either at the time of their original publication. To our listeners, please do not consume any products from this brand, as they have already been associated with <a target="_blank" href="https://www.cbsnews.com/news/recalled-diamond-shruumz-edibles/">113 illnesses and 2 deaths nationwide</a>. </p><p></p><p></p> <br/><br/>Get full access to Neural Pharm at <a href="https://neuralpharm.substack.com/subscribe?utm_medium=podcast&utm_campaign=CTA_4">neuralpharm.substack.com/subscribe</a>
24 total episodes available
Deep-dive analytics for Neural Pharm Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Neural Pharm Podcast?
- How often does this podcast release new episodes?
This podcast updates bi-weekly.
- Where can I listen to this podcast?
This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.